BACKGROUND: Enoxaparin 30 mg twice daily and dalteparin 5,000 units once daily are two common low-molecular-weight heparin (LMWH) thromboprophylaxis regimens used in the trauma population. Pharmacodynamic studies suggest that enoxaparin provides more potent anticoagulation than does dalteparin.
Effective thromboprophylaxis is essential in the trauma population. VTE is the third most common complication in trauma patients, 1 and pulmonary embolism (PE) is the third most common cause of death in patients surviving the first 24 hours after an injury. 2 Noting its importance, key stakeholders, such as the Centers for Medicare & Medicaid Services, have identified the incidence of VTE as a quality of care metric for all hospitalized patients. 3, 4 Enoxaparin and dalteparin are the two most widely used low-molecular-weight heparin (LMWH) agents in North America. Although LMWHs are considered the gold standard for use in trauma patients, 5 only enoxaparin has proven efficacy in this population. [6] [7] [8] Enoxaparin and dalteparin exhibit important differences in molecular size, clearance, and relative affinity for factor Xa vs factor IIa and are not considered interchangeable by the US Food and Drug administration. 9, 10 No randomized trials have tested dalteparin in trauma patients, 8 whereas two observational studies comparing the agents provide inconclusive results. 11, 12 Pharmacodynamic studies in healthy volunteers suggest that subcutaneous prophylactic doses of enoxaparin provide 30% to 100% greater factor Xa inhibition than does subcutaneous dalteparin on a per-unit basis. 13, 14 Importantly, how these data extrapolate to a real-world trauma population is unknown.
Most institutions in the United States carry only one LMWH (either enoxaparin or dalteparin) on formulary at any one time. If these agents have different effectiveness, their interchange in the trauma population could be an important source of excess VTE complications. However, no large-scale study has addressed this important knowledge gap. Formulary changes over time at our institution have resulted in the conversion from enoxaparin to dalteparin and back to enoxaparin for VTE prophylaxis in trauma patients. These changes created a natural experiment that allowed us to compare enoxaparin and dalteparin in a real-world trauma population.
Methods

Study Design
In December 2009, the study institution's acquisition cost of dalteparin decreased, prompting a formulary switch from enoxaparin to dalteparin. The cost of dalteparin later increased, resulting in a switch back to enoxaparin in February 2013. A study leveraging the resulting natural experiment can provide strong control of confounding by indication, 15 because the change in LMWH was due to cost fluctuations and not perceived differences in efficacy. In addition, the removal and reintroduction of enoxaparin reduces bias from temporal variation in risk factors, VTE surveillance, 16, 17 and overall quality of care. 18 Temporal bias was also reduced by including a concurrent control group of trauma patients who received unfractionated heparin (UFH). 18 According to local practice, UFH was prescribed preferentially to trauma patients with traumatic brain injury, spinal cord injury, or reduced renal function, or to those undergoing epidural analgesia. The control patients receiving UFH were cared for by the same providers in the same units and were subject to the same VTE surveillance as the LMWH group. The Institutional Review Board of the University of Pennsylvania approved the study and waived informed consent (IRB No. 7, protocol 818037).
Study Population
Patients were drawn from the Hospital of the University of Pennsylvania, an academic level 1 trauma center in Philadelphia Pennsylvania. Inclusion criteria were admission from January 1, 2004 to March 1, 2014, age $ 18 years, receipt of $ 24 hours of prophylaxis initiated within 48 hours of admission, and presence of one or more VTE risk factors, including lower-extremity fracture, pelvic fracture, spinal cord injury, traumatic brain injury, transfusion in the ED, age $ 40 years, history of prior VTE, malignancy, or ICU admission. 5, [19] [20] [21] Patients were excluded for crossover between dalteparin and enoxaparin, receipt of $ 24 hours of a second anticoagulant within 48 hours of admission, active VTE on admission, or missing covariate data. This latter criterion was not applied to missing height or weight (or both), given the high prevalence of missingness for these covariates. We addressed missing data through multiple imputation (e-Appendix 1).
VTE Prophylaxis
The prophylaxis guideline recommended combined LMWH and mechanical prophylaxis with sequential compression devices. Patients were surveilled for VTE with lower extremity ultrasonography for 3 weeks after injury while in the hospital. Enoxaparin 30 mg twice daily was the standard LMWH during the enoxaparin periods, whereas dalteparin 5,000 units once daily was the standard during the dalteparin period. The standard UFH regimen was 5,000 units three times daily throughout the entire study period. We assumed prophylaxis could not prevent VTE events diagnosed on the day of prophylaxis initiation. Thus, follow-up began 24 hours after the first dose and continued until 48 hours after the last dose, initiation of a different prophylaxis regimen, occurrence of VTE, hospital discharge, death, or until hospital day 30, whichever came first.
Data Sources and Variables
Patients were identified from a local registry that conforms to state reporting guidelines as set forth by the Pennsylvania Trauma System Foundation (PTSF). Specially trained registrars abstract data prospectively according to standardized definitions, and data quality is monitored by PTSF through data audits. The registry is frequently used for research. [22] [23] [24] The registry contains demographics, injury characteristics, Injury Severity Score, 25 comorbidities, and complications.
Registry data were linked to data from a health system-wide data warehouse 26 that contains medications, discharge diagnosis data, orders for sequential compression devices and duplex ultrasonographic examinations, level of care (ICU vs ward), and laboratory results.
Outcomes
The primary outcome was inhospital 30-day VTE, a composite of PE and lower-extremity DVT. VTE was queried from the trauma registry and from hospital discharge diagnosis codes (e- Table 1 ). All VTEs identified through query were validated with chart review (see e-Appendix 1 for complete definitions). In a prior validation study, we demonstrated complete capture of VTE with this method. 27 Secondary outcomes were PE, proximal DVT, all DVT, and a composite of VTE and all-cause hospital mortality (to account for the competing risk of mortality 28, 29 and to capture undiagnosed fatal PE).
Statistical Analysis
Baseline covariates were summarized with descriptive statistics. Covariate balance was assessed using standardized differences (SDF), 30, 31 with SDF > 0.1 considered an important imbalance. 31 VTE occurrence was expressed as the number of incident VTEs/ 1,000 person-days. A difference-in-differences (DID) analysis 18,32 was used to contrast the change in VTE rate accompanying the LMWH switch with the change in VTE rate in UFH control subjects. 
where i is the patient, j is the prophylaxis group (LMWH vs UFH), and t is the formulary period (enoxaparin vs dalteparin). Regression coefficients are interpreted as follows: b1 is the difference in VTE between the dalteparin period and the enoxaparin periods, b2 is the difference in VTE between patients receiving LMWH and control subjects receiving UFH, and b3 is the DID term. If the DID term is positive, this implies that the VTE rate increased more among patients receiving LMWH than among the control patients receiving UFH during the dalteparin period. Thus, b3 represents the treatment effect of the formulary switch to dalteparin. Potential confounding was evaluated using a change-in-estimate approach. 33, 34 Each covariate (Table 1 ) was added to the base model individually. Covariates that changed the DID term by $ 10% were retained in the final model. Statistical inference was based on the 95% CIs around the DID point estimates. 35, 36 All analyses were conducted using Stata/SE, version 14.2 (StataCorp, LLC). Details of model validation procedures can be found in e-Appendix 1.
Sensitivity Analyses
We examined the robustness of our findings in several sensitivity analyses: (1) repeating analysis using negative binomial regression, (2) restricting analysis to patients who underwent one or more surveillance ultrasonographic examinations, (3) censoring follow-up at the time of the last dose, (4) excluding patients admitted before January 2007, (5) including patients with missing data using multiple imputation (e-Appendix 1), (6) restricting analysis to patients who received prophylaxis within 24 hours of admission, (7) restricting analysis to patients who missed < 20% of scheduled doses (post hoc analysis), and (8) restricting analysis to patients who missed < 20% of scheduled doses who also received prophylaxis within 24 hours of admission (post hoc analysis). Missed-dose tabulation methods and results are detailed in e-Appendix 1, e- Table 2 .
Results
We included 5,880 patients (Fig 1) : 3,910 patients during the enoxaparin period (enoxaparin, n ¼ 2,371; UFH control subjects, n ¼ 1,539) and 1,970 patients during the dalteparin period (dalteparin, n ¼ 1,046; UFH control subjects, n ¼ 924). Patients receiving enoxaparin and those receiving dalteparin had similar age, sex, body size, injury mechanism, baseline renal function, and comorbid illnesses ( Table 1) . As expected, the control patients receiving UFH differed from the patients receiving LMWH, reflecting the different indications for UFH vs LMWH as dictated by the prophylaxis guideline. UFH control subjects had a higher prevalence of traumatic brain injury, spinal cord injury, epidural analgesia, and lower baseline renal function. However, the characteristics of the UFH control subjects generally changed little over time. The control patients receiving UFH in the enoxaparin vs dalteparin periods showed similar age, sex, body size, injury mechanism, baseline renal function, and comorbid illnesses. Some characteristics changed over time in both the LMWH and UFH control groups: Injury Severity Score, baseline platelet count, use of mechanical prophylaxis, and incidence of surgical procedures. However, the magnitude and direction of the temporal changes were similar between the LMWH and UFH control groups. Finally, a change in VTE surveillance over time was similar in the LMWH and UFH control groups (e- Table 3 ). There were 190 VTE events, with most (65.3%) occurring during the first 5 days (Fig 2) . PE occurred in 46 patients, whereas isolated DVT occurred in 144 patients, with 73 of these being proximal events. Seven patients with PE had concomitant DVT. Thirty-day chestjournal.org inpatient mortality was higher in patients with VTE than in those without: 11 of 190 patients (5.8%) vs 105 of 5,690 patients (1.9%); relative risk, 3.3; 95% CI, 1.7-5.7. The primary analysis is shown in Table 3 . The unadjusted DID estimate was 1.25 (95% CI, 0.69-2.29). Adjustment for confounding attenuated the estimate to 1.06 (95% CI, 0.71-2.00), consistent with a negligible difference in effectiveness between enoxaparin and dalteparin, albeit with a fairly wide CI. Similar patterns were observed for the secondary outcomes (Table 3) .
Results were robust regarding the choice of statistical model, length of follow-up after the last dose, changes in period, and changes in ultrasonographic surveillance (Table 3) . Our results were also similar in the multiple imputation analysis (e-Appendix 1, e-Tables 4-7).
The DID estimate increased when we restricted analysis to patients who had prophylaxis initiated within 24 hours of admission (n ¼ 3,203) or to patients who missed < 20% of scheduled doses (n ¼ 4,625). Further restriction to patients who received prophylaxis within 24 hours of admission while also missing < 20% of scheduled doses (n ¼ 2,457) resulted in a DID of 2.39 (95% CI, 0.80-7.09).
Discussion
The goal of comparative effectiveness research is to examine the benefits and harms of treatments in realworld settings. 37 Implicit in this aim is a recognition that findings from highly controlled trials or preclinical settings, or both, may not translate to everyday practice. 37 This idea is particularly relevant to thromboprophylaxis in trauma, in which patients with a high risk for thrombosis may also experience delayed or interrupted prophylaxis because of surgery or bleeding. Against this backdrop, we compared the two most widely used LMWH regimens in the trauma population. Despite pharmacodynamic data suggesting substantial differences in anticoagulant potency, we observed similar rates of VTE with enoxaparin and dalteparin. Exclusion of patients with prophylaxis delays or interruptions (or both) produced estimates in favor of enoxaparin. Although these secondary findings should be viewed as hypothesis generating only, they suggest that differences in potency may be relevant only in patients who receive early and consistent prophylaxis.
Although no randomized trials have addressed this question, two retrospective studies are relevant. Slavik et al 11 studied 135 trauma patients and found a numeric imbalance suggesting a higher rate of VTE with dalteparin than with enoxaparin: 9.7% vs 1.6%, respectively (difference, 8.1% [95% CI, -0.6% to 15.6%]; P ¼ .1), but the small sample size precluded definitive conclusions. A second study of 610 trauma patients showed similar effectiveness (enoxaparin, 5.1% vs dalteparin, 4.5%; difference, 0.5% [95% CI, -2.9% to 4.0%]; P ¼ .85), but the study included patients with delayed prophylaxis, potentially blunting differences in effectiveness. 12 Our results extend these findings, suggesting that the enoxaparin and dalteparin regimens provide similar protection against VTE in a real-world trauma setting.
LMWH is presumed to inhibit coagulation primarily through inhibition of factor Xa. 10 Our primary results thus seem inconsistent with the apparent differences in anti-FXa activity produced by the two LMWH regimens. 9,10,13,14, 38 Collignon et al 14 showed that prophylactic doses of enoxaparin provided 2.4-fold higher anti-FXa activity per 1,000 international units vs dalteparin.
14 Similar results were observed in a study by Bendz et al. 38 The higher anti-FXa activity of enoxaparin would be expected to reduce VTE rates. However, the antithrombotic effect of LMWHs may be mediated by other mechanisms. 9, 10 LMWHs cause release of tissue factor pathway inhibitor (TFPI), 39 and the degree of TFPI release does not mirror anti-FXa activity. 10, 38 LMWHs also have variable effects on factor IIa, von Willebrand factor, and thrombin-activatable fibrinolysis inhibitor. 10, 40, 41 Consequently, the global antithrombotic effects of the two LMWHs may be similar despite differences in measured anti-FXa activity.
Our primary analysis was designed to measure effectiveness, which focuses on real-world effects as opposed to effects under ideal conditions (ie, efficacy). 37 Thus, patients were included regardless of missed or delayed prophylaxis initiation (or both), factors that may substantially reduce the benefit of LMWH prophylaxis. [42] [43] [44] Restriction of our analysis to patients who received early (within 24 hours) and consistent (> 80% of scheduled doses) treatment with LMWH produced an estimate that favored enoxaparin. This result could be viewed as a measure of the comparative efficacy of the two regimens, rather than effectiveness, as it derives from a population that more closely represents "ideal conditions." It should be noted, however, that the The difference-in-differences parameter represents the relative difference in the RR between treatment groups. It is interpreted as follows: the relative increase of VTE rate in LMWH-exposed patients after the switch was 6% larger than the relative increase in UFH control subjects. The difference-in-differences parameter represents the relative difference in the rate ratio between treatment groups.
CIs around these post hoc sensitivity estimates are considerably wider, overlapping with the results of the primary analysis. These caveats notwithstanding, the findings generate plausible hypotheses that may help to explain discrepancies between efficacy and effectiveness in studies of VTE thromboprophylaxis in trauma patients.
VTE can occur very early after injury, 45 with most cases occurring by day 5 in our study. Consequently, thrombosis may have already been developing at the time of prophylaxis initiation in many patients, blunting differences in anticoagulation efficacy provided by the two LMWH regimens. Missed doses may similarly blunt differences in efficacy by allowing clot formation during periods of low exposure after a missed dose. The cumulative effect of such gaps in prophylaxis could potentially mask differences in anticoagulation potency between the enoxaparin and dalteparin regimens. Although these factors represent targets for intervention, the extent to which they are modifiable is unclear. Our results suggest that additional research is needed to understand whether and how the timing and consistency of prophylaxis alters LMWH comparative effectiveness.
Our study has limitations. Although our primary results are most consistent with similar effectiveness, the CIs do not rule out potentially important differences. Additional studies in larger populations are needed to increase precision. It is possible that our results are biased by unmeasured factors that changed differentially over time in the LMWH group vs the UFH control group. We minimized such bias by virtue of our study design and analysis approach. In addition, we adjusted for important VTE risk factors. However, as with any nonrandomized design, the possibility of residual bias cannot be eliminated. Our results stem from a single center, potentially limiting generalizability. In addition, we could not distinguish symptomatic vs asymptomatic VTE. Ideally, the analysis would focus on symptomatic events, but such an approach was not feasible for multiple reasons. First, adequate documentation of the requisite information on symptoms is largely absent in the electronic medical record. Second, the signs and symptoms of VTE are very nonspecific in trauma and other critically ill populations. Additional research in this area is needed. Finally, we could not measure bleeding because of a lack of validated algorithms to identify bleeding retrospectively. In addition, data on transfusions were only available after the year 2010 in our database, precluding the use of this variable as an outcome in the analysis. Alternatively, we could have derived a variable related to drops in hemoglobin values; however, we judged this approach to lack sufficient specificity in the trauma population, which experiences drops in hemoglobin values for reasons other than bleeding (eg, anemia of critical illness, dilutional effects of fluid resuscitation). Prior evidence suggests that bleeding rates are low with both regimens. 8 
Conclusions
We observed similar effectiveness for dalteparin vs enoxaparin in a real-world trauma population. Future research should investigate how the timing and consistency of prophylaxis delivery affects LMWH effectiveness.
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